In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Annabel Samimy, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Altimmune (ALT).Stay Ahead of the Market:Discover ...

Life without a pancreas involves treatments to replace organ function. Learn how different surgical techniques affect overall ...

Stifel analyst Annabel Samimy initiated coverage of Altimmune (ALT) with a Buy rating and $18 price target The company is developing ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

LBT-3627 is under clinical development by Longevity Biotech and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease ha ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...